{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T04:00:10Z","timestamp":1791259210896,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11739-019-02253-7","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T12:02:43Z","timestamp":1576584163000},"page":"199-210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Intravitreal anti-VEGF agents and cardiovascular risk"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3407-6017","authenticated-orcid":false,"given":"Massimo","family":"Porta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Striglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"2253_CR1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger DR, Galli SJ, Dvorak AM et al (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983\u2013985","journal-title":"Science"},{"key":"2253_CR2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","volume":"161","author":"N Ferrara","year":"1989","unstructured":"Ferrara N, Henzel WJ (1989) Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 161:851\u2013858","journal-title":"Biochem Biophys Res Commun"},{"issue":"8","key":"2253_CR3","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0143-4004(97)90007-2","volume":"18","author":"VH Shore","year":"1997","unstructured":"Shore VH, Wang TH, Wang CL et al (1997) Vascular endothelial growth factor, placenta growth factor and their receptors in isolated human trophoblast. Placenta 18(8):657\u2013665","journal-title":"Placenta"},{"key":"2253_CR4","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/j.1462-5822.2012.01802.x","volume":"14","author":"LM Wise","year":"2012","unstructured":"Wise LM, Inder MK, Real NC et al (2012) The vascular endothelial growth factor (VEGF)-E encoded by orf virus regulates keratinocyte proliferation and migration and promotes epidermal regeneration. Cell Microbiol 14:1376\u20131390","journal-title":"Cell Microbiol"},{"issue":"284","key":"2253_CR5","doi-asserted-by":"publisher","first-page":"9885","DOI":"10.1074\/jbc.M809071200","volume":"10","author":"Y Yamazaki","year":"2009","unstructured":"Yamazaki Y, Matsunaga Y, Tokunaga Y et al (2009) Snake venom Vascular Endothelial Growth Factors (VEGF-Fs) exclusively vary their structures and functions among species. J Biol Chem 10(284):9885\u20139891","journal-title":"J Biol Chem"},{"issue":"10","key":"2253_CR6","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","volume":"19","author":"K Holmes","year":"2007","unstructured":"Holmes K, Roberts O, Angharad M et al (2007) Vascular endothelial growth factor receptor 2: structure, function, intracellular signaling and therapeutic inhibition. Cell Signal 19(10):2003\u20132012","journal-title":"Cell Signal"},{"key":"2253_CR7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1242\/dev.103028","volume":"141","author":"A Fantin","year":"2014","unstructured":"Fantin A, Herzog B, Mahmoud M et al (2014) Neuropilin 1 (NRP-1) hypomorphism combined with defective VEGF-A binding reveals novel roles for NRP-1 in developmental and pathological angiogenesis. Development 141:556\u2013562","journal-title":"Development"},{"key":"2253_CR8","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.ajpath.2013.05.031","volume":"183","author":"N Beasley_Long","year":"2013","unstructured":"Beasley_Long N, Hua J, Jehle T et al (2013) VEGF-A 165b is an endogenous neuroprotective splice isoform of vascular endothelial growth factor A in vivo and in vitro. Am J Pathol 183:918\u2013929","journal-title":"Am J Pathol"},{"issue":"12","key":"2253_CR9","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1042\/CS20170102","volume":"131","author":"N Ved","year":"2017","unstructured":"Ved N, Hulse RP, Bestall SM et al (2017) Vascular endothelial factor-A 165b ameliorates outer retinal barrier and vascular dysfunction in diabetic retina. Clin Sci 131(12):1225\u20131243","journal-title":"Clin Sci"},{"issue":"6","key":"2253_CR10","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Investig 119(6):1420\u20131428","journal-title":"J Clin Investig"},{"issue":"4","key":"2253_CR11","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1083\/jcb.124.4.619","volume":"124","author":"SM Frisch","year":"1994","unstructured":"Frisch SM, Francis H (1994) Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 124(4):619\u2013626","journal-title":"J Cell Biol"},{"key":"2253_CR12","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1038\/430973a","volume":"430","author":"LA Liotta","year":"2004","unstructured":"Liotta LA, Kohn E (2004) Anoikis: cancer and homeless cell. Nature 430:973\u2013974","journal-title":"Nature"},{"key":"2253_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1006\/bbrc.1993.1671","volume":"193","author":"AP Adams","year":"1993","unstructured":"Adams AP, Shima DT, Yeo KT et al (1993) Synthesis and secretion of vascular permeability factor\/vascular endothelial growth factor by human retinal pigmental cells. Biochem Biophys Res Commun 193:631\u2013638","journal-title":"Biochem Biophys Res Commun"},{"key":"2253_CR14","first-page":"1868","volume":"35","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Ferrara N, King GL (1994) Hypoxic regulation and bioactivity of vascular endothelial growth factor: characterization in retinal microvascular pericytes and pigment epithelial cells. Invest Ophthalmol Vis Sci 35:1868","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2253_CR15","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2337\/diacare.21.1.143","volume":"21","author":"LP Aiello","year":"1998","unstructured":"Aiello LP, Gardner TW, King GL et al (1998) Diabetic retinopathy. Diabetes Care 21:143\u2013156","journal-title":"Diabetes Care"},{"issue":"7","key":"2253_CR16","first-page":"666","volume":"99","author":"MI Lin","year":"2006","unstructured":"Lin MI et al (2006) Vascular endothelial growth factor signalling to endothelial nitric oxide synthase: more than a FleeTing moment. Clin Res 99(7):666\u2013668","journal-title":"Clin Res"},{"key":"2253_CR17","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.1242\/jcs.115972","volume":"126","author":"A Di Lorenzo","year":"2013","unstructured":"Di Lorenzo A, Lin MI, Murata T et al (2013) eNOS derived nitric oxide regulates endothelial barrier function through VE-cadherin and Rho GTPases. J Cell Sci 126:5541\u20135552","journal-title":"J Cell Sci"},{"issue":"7","key":"2253_CR18","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2174\/1389200216666151001120831","volume":"16","author":"F Semeraro","year":"2015","unstructured":"Semeraro F, Morescalchi F, Duse S et al (2015) Pharmacokinetic and oharmacodynamic properties of anti_VEGF drugs after intravitreal injection. Curr Drug Metab 16(7):572\u2013584","journal-title":"Curr Drug Metab"},{"key":"2253_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2174\/1568008013341073","volume":"1","author":"G Ranieri","year":"2001","unstructured":"Ranieri G, Gasparini G (2001) Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy. Current Drugs Targets Immune Endocr Metabol Disord 1:241\u2013253","journal-title":"Current Drugs Targets Immune Endocr Metabol Disord"},{"key":"2253_CR20","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/35025215","volume":"407","author":"GD Yancopoulos","year":"2000","unstructured":"Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular specific growth factors and blood vessel formation. Nature 407:242\u2013248","journal-title":"Nature"},{"issue":"1","key":"2253_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12079-017-0433-3","volume":"12","author":"S Kazerounian","year":"2018","unstructured":"Kazerounian S, Lawler J (2018) Integration of pro and anti angiogenic signals by endothelial cells. J Cell Commun Signal 12(1):171\u2013179","journal-title":"J Cell Commun Signal"},{"key":"2253_CR22","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0002-9440(10)63042-8","volume":"159","author":"J Lawler","year":"2001","unstructured":"Lawler J, Miao WM, Duquette M et al (2001) Thrombospondin-1 gene expression affects survival and tumor spectrum of p53 deficient mice. Am J Pathol 159:1949\u20131956","journal-title":"Am J Pathol"},{"key":"2253_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.tem.2013.09.005","volume":"25","author":"R Sim\u00f2","year":"2014","unstructured":"Sim\u00f2 R, Hernandez C (2014) Neurodegeneration in diabetic eye: new insights and therapeutic perspectives. Trend Endocrinol Metab 25:23\u201333","journal-title":"Trend Endocrinol Metab"},{"issue":"11","key":"2253_CR24","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1172\/JCI119451","volume":"99","author":"M Ziche","year":"1997","unstructured":"Ziche M, Morbidelli L, Choudhuri R et al (1997) Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 99(11):2625\u20132634","journal-title":"J Clin Invest"},{"key":"2253_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/sj.bjp.0703393","volume":"130","author":"AS De Vriese","year":"2000","unstructured":"De Vriese AS, Verbeuren TJ, Van de Voorde J et al (2000) Endothelial dysfunction in diabetes. Br J Pharmacol 130:963\u2013974","journal-title":"Br J Pharmacol"},{"key":"2253_CR26","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/414813a","volume":"4141","author":"M Brownlee","year":"2001","unstructured":"Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 4141:813\u2013820","journal-title":"Nature"},{"issue":"6","key":"2253_CR27","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2337\/diabetes.47.6.859","volume":"47","author":"D Koya","year":"1998","unstructured":"Koya D, King GL (1998) Protein kinase C activation and the development of diabetic complications. Diabetes 47(6):859\u2013866","journal-title":"Diabetes"},{"key":"2253_CR28","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1464-5491.2010.03210.x","volume":"28","author":"AK Sj\u00f8lie","year":"2011","unstructured":"Sj\u00f8lie AK, Klein R, Porta M et al (2011) Retinal microaneurisms count predicts progression and regression of diabetic retinopathy. Post hoc results from the DIRECT Programme. Diabet Med 28:345\u2013351","journal-title":"Diabet Med"},{"key":"2253_CR29","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.exer.2015.01.023","volume":"132","author":"AM Abu El-Asar","year":"2015","unstructured":"Abu El-Asar AM, De Hertogh G, Van den Eynde K et al (2015) Myofibroblasts in proliferative diabetic retinopathy can originate from infiltrating fibrocytes and through endothelial-to mesenchymal transition (EndoMIT). Exp Eye es 132:179\u2013189","journal-title":"Exp Eye es"},{"key":"2253_CR30","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. NEJM 331:1480\u20131487","journal-title":"NEJM"},{"key":"2253_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/2156273","author":"P Romero-Aroca","year":"2016","unstructured":"Romero-Aroca P, Baget-Bernaldiz M, Pareia-Rios A et al (2016) Diabetic macular edema pathophysiology: vasogenic versus inflammatory. J Diab Res. https:\/\/doi.org\/10.1155\/2016\/2156273(2156273 Epub 2)","journal-title":"J Diab Res"},{"key":"2253_CR32","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1007\/s00125-005-1951-8","volume":"48","author":"RM Perrin","year":"2005","unstructured":"Perrin RM, Konopatsakaya O, Qiu Y et al (2005) Diabetic retinopathy is associated with a switch in splicing from anti to pro-angiogenic isoform of vascular endothelial growth factor. Diabetologia 48:2422\u20132427","journal-title":"Diabetologia"},{"key":"2253_CR33","first-page":"626","volume":"12","author":"O Konopatsakaya","year":"2006","unstructured":"Konopatsakaya O, Churchill AJ, Harper SJ et al (2006) VEGF 165b an endogenous C terminal splice variant of VEGF inhibits retinal neovascularization in mice. Mol Vis 12:626\u2013632","journal-title":"Mol Vis"},{"key":"2253_CR34","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1167\/iovs.09-4360","volume":"51","author":"J Hua","year":"2010","unstructured":"Hua J, Spee C, Kase S et al (2010) Recombinant human VEGF 165b inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 51:4282\u20134288","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2253_CR35","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1167\/iovs.09-4296","volume":"51","author":"AL Magnussen","year":"2010","unstructured":"Magnussen AL, Rennel ES, Hua J et al (2010) VEGF-A 165b is cytoprotective and antiangiogenic in the retina. Invest Ophthalmol Vis Sci 51:4272\u20134281","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"2253_CR36","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.ophtha.2013.11.041","volume":"121","author":"U Schmidt-Erfurth","year":"2014","unstructured":"Schmidt-Erfurth U, Lang GE, Holz FG et al (2014) Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121(5):1045\u20131053","journal-title":"Ophthalmology"},{"key":"2253_CR37","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","volume":"314","author":"JC Gross","year":"2015","unstructured":"Gross JC, Glassman AR (2015) Writing Committee for the Diabetic Retinopathy Clinical Research Network. Panretinal photocoagulation vs intravenous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA 314:2137\u20132146","journal-title":"JAMA"},{"key":"2253_CR38","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, Mc Donald DM (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788\u20131798","journal-title":"Br J Cancer"},{"issue":"2","key":"2253_CR39","doi-asserted-by":"publisher","first-page":"132","DOI":"10.2174\/157488408784293705","volume":"3","author":"JM Roodhart","year":"2008","unstructured":"Roodhart JM, Lanenberg MH, Witteveen E, Voest EE (2008) The molecular basis of class side effects due to treatment with inhibitors of the VEGF\/VEGFR pathway. Curr Clin Pharmacol 3(2):132\u2013143","journal-title":"Curr Clin Pharmacol"},{"key":"2253_CR40","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.pharmthera.2017.08.012","volume":"182","author":"M Li","year":"2018","unstructured":"Li M, Kroetz DL (2018) Bevacizumab-induced hypertension: clinical presentation and molecular understanding. Pharmacol Ther 182:152\u2013160","journal-title":"Pharmacol Ther"},{"key":"2253_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1056\/NEJM199807233390404","volume":"339","author":"SM Haffner","year":"1998","unstructured":"Haffner SM, Lehto S, Ronnemea T et al (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and non diabetic subjects with and without prior myocardial infarction. NEJM 339:229\u2013234","journal-title":"NEJM"},{"key":"2253_CR42","doi-asserted-by":"publisher","first-page":"162","DOI":"10.2337\/dc07-9917","volume":"30","author":"JB Buse","year":"2007","unstructured":"Buse JB, Ginsberg HN, Bakris GL et al (2007) American Heart Association; American Diabetes Association: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 30:162\u2013172","journal-title":"Diabetes Care"},{"issue":"3","key":"2253_CR43","doi-asserted-by":"publisher","first-page":"e5894","DOI":"10.1097\/MD.0000000000005894","volume":"96","author":"XR Zhu","year":"2017","unstructured":"Zhu XR, Zhang YP, Bai L et al (2017) Prediction of risk of diabetic retinopathy for all-cause mortality, stroke and heart failure Evidence from epidemiological, observational studies. Medicine 96(3):e5894. https:\/\/doi.org\/10.1097\/MD.0000000000005894","journal-title":"Medicine"},{"issue":"1","key":"2253_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1573399812666151012115355","volume":"13","author":"N Shoeibi","year":"2017","unstructured":"Shoeibi N, Bonakdaran S (2017) Is There any correlation between diabetic retinopathy and risk of cardiovascular disease? Curr Diabetes Rev 13(1):81\u201386","journal-title":"Curr Diabetes Rev"},{"key":"2253_CR45","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.2337\/dc15-2671","volume":"39","author":"J Sanahuja","year":"2016","unstructured":"Sanahuja J, Alonso N, Diez J et al (2016) Increased burden of cerebral small vessel disease in patients with type 2 diabetes and retinopathy. Diabetes Care 39:1614\u20131620","journal-title":"Diabetes Care"},{"key":"2253_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2415-12-11","volume":"12","author":"BA Nguyen-Khoa","year":"2012","unstructured":"Nguyen-Khoa BA, Goehring EL, Werther W et al (2012) Hospedalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol 12:11. https:\/\/doi.org\/10.1186\/1471-2415-12-11","journal-title":"BMC Ophthalmol"},{"key":"2253_CR47","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1136\/hrt.2008.146670","volume":"95","author":"G Liew","year":"2009","unstructured":"Liew G, Wong TI, Mitchell P et al (2009) Retinopathy predicts coronary heart disease mortality. Heart 95:391\u2013394","journal-title":"Heart"},{"issue":"9","key":"2253_CR48","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/j.ophtha.2014.03.026","volume":"121","author":"X Li","year":"2014","unstructured":"Li X, Xu G, Wang Y et al (2014) Safety and efficacy of combercept in neovascular age-related macular degeneration:results from 12 month randomized phase 2 study: AURORA study. Ophthalmology 121(9):1740\u20131747","journal-title":"Ophthalmology"},{"key":"2253_CR49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1146\/annurev-pharmtox-010611-134654","volume":"55","author":"A Pluckthun","year":"2015","unstructured":"Pluckthun A (2015) Designed ankyrin repeat proteins (DARPns): binding proteins for research, diagnostics, and therapy. Annu Rev Phaarmacol Toxicol 55:489\u2013511","journal-title":"Annu Rev Phaarmacol Toxicol"},{"issue":"11","key":"2253_CR50","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1136\/bjo.2006.102293","volume":"90","author":"S Michels","year":"2006","unstructured":"Michels S (2006) Is intravitreal bevacizumab (Avastin) safe? Br J Ophthalmol 90(11):1333\u20131334","journal-title":"Br J Ophthalmol"},{"key":"2253_CR51","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"27","author":"RL Avery","year":"2017","unstructured":"Avery RL, Castellarin AA, Steinle NC et al (2017) Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab and ranibizumab. Retina 27:1847\u20131858","journal-title":"Retina"},{"key":"2253_CR52","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1167\/iovs.12-10260","volume":"54","author":"L Xu","year":"2013","unstructured":"Xu L, Lu T, Tuomi L et al (2013) Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest Ophthalmol Vis Sci 54:1616\u20131624","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"2253_CR53","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1136\/bjo.2008.156810","volume":"94","author":"K Matsuyama","year":"2010","unstructured":"Matsuyama K, Ogata N, Matsuoka M et al (2010) Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after injection of bevacizumab. Br J Ophthalmol 94(9):1215\u20131218","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"2253_CR54","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","volume":"37","author":"RL Avery","year":"2017","unstructured":"Avery RL et al (2017) Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab and ranibizumab. Retina 37(10):1847\u20131858","journal-title":"Retina"},{"key":"2253_CR55","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.ophtha.2018.01.019","volume":"125","author":"Lee","year":"2018","unstructured":"Lee et al (2018) Plasma vascular endothelial growth factor concentrations after intravitreous anti-vascular endothelial growth factor therapy for diabetic macular edema. Ophthalmology 125:1054\u20131063","journal-title":"Ophthalmology"},{"key":"2253_CR56","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-019-01416-4","author":"C Busch","year":"2019","unstructured":"Busch C, Frazer-Bell S, Iglicki M et al (2019) Real-world outcomes of non-responding diabetic macular edema treated with continued anti-VEGF therapy versus early switch to dexamethasone implant: 2-year results. Acta Diabetol. https:\/\/doi.org\/10.1007\/s00592-019-01416-4","journal-title":"Acta Diabetol"},{"issue":"1","key":"2253_CR57","first-page":"63","volume":"7","author":"MA Zarbin","year":"2018","unstructured":"Zarbin MA (2018) Anti-VEGF agents and the risk of arteriothrombotic events. Asia Pac J Ophthalmol 7(1):63\u201367","journal-title":"Asia Pac J Ophthalmol"},{"issue":"1","key":"2253_CR58","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","volume":"246","author":"L Wu","year":"2008","unstructured":"Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al (2008) Twelve month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 246(1):81\u201387","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"8","key":"2253_CR59","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1001\/archophthalmol.2012.393","volume":"130","author":"R Rajendram","year":"2012","unstructured":"Rajendram R, Fraser-Bell S, Kaines A et al (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the mnagment of diabetic macular edema: 24 month data:report 3. Arch Ophthalmol 130(8):972\u2013979","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"2253_CR60","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12886-017-0586-0","volume":"17","author":"J Hanhart","year":"2017","unstructured":"Hanhart J, Comaneshter DS, Freier Dror Y et al (2017) Mortality in patients treated with intravitreal bevacizumab for age related macular degeneration. BMJ Ophthalmol 17(1):189. https:\/\/doi.org\/10.1186\/s12886-017-0586-0","journal-title":"BMJ Ophthalmol"},{"issue":"10","key":"2253_CR61","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"DM Brown","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM et al (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120(10):2013\u20132022","journal-title":"Ophthalmology"},{"key":"2253_CR62","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","volume":"123","author":"JS Hejer","year":"2016","unstructured":"Hejer JS, Korobelnik JF, Brown DM et al (2016) Intravitreal aflibercept for diabetic macular edema: 148 week results from VISTA and VIVID studies. Ophthalmology 123:2376\u20132385","journal-title":"Ophthalmology"},{"key":"2253_CR63","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.exer.2018.06.009","volume":"175","author":"B Sobolewska","year":"2018","unstructured":"Sobolewska B, Golenko J, Poeschel S et al (2018) Influence of aflibercept on platelet activation profile. Exp Eye Res 175:166\u2013172","journal-title":"Exp Eye Res"},{"issue":"4","key":"2253_CR64","doi-asserted-by":"publisher","first-page":"e96402","DOI":"10.1371\/journal.pone.0096402","volume":"9","author":"J Etulain","year":"2014","unstructured":"Etulain J, Negrotto S, Tribulatti MV et al (2014) Control of angiogenesis by galectin involves the release of platelet derived proangiogenic factors. PLoS ONE 9(4):e96402. https:\/\/doi.org\/10.1371\/journal.pone.0096402","journal-title":"PLoS ONE"},{"issue":"2","key":"2253_CR65","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1167\/iovs.13-12812","volume":"1055","author":"H Ameri","year":"2014","unstructured":"Ameri H, Liu H, Liu R et al (2014) TWEAK\/Fn14 pathway is a novel mediator of retinal neovascularization. Invest Ophthalmol Cis Sci 1055(2):801\u2013813","journal-title":"Invest Ophthalmol Cis Sci"},{"key":"2253_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005139.pub4","author":"SD Solomon","year":"2014","unstructured":"Solomon SD, Lindsley K, Vedula SS et al (2014) Anti-vascular endothelial growth factor for neovascular age related macular degeneration. Cochrane Database Syst. https:\/\/doi.org\/10.1002\/14651858.CD005139.pub4","journal-title":"Cochrane Database Syst"},{"issue":"1","key":"2253_CR67","first-page":"138","volume":"8","author":"WJ Wang","year":"2015","unstructured":"Wang WJ, Chen J, Zhang XL et al (2015) Bevacizumab versus ranibizumab for neovascular age related macular degeneration: a meta-analysis. Int J Ophthalmol 8(1):138\u2013147","journal-title":"Int J Ophthalmol"},{"key":"2253_CR68","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/eye.2013.1","volume":"27","author":"FG Ahfat","year":"2013","unstructured":"Ahfat FG, Zaidi FH (2013) Bevacizumab vs ranibizumab\u2014an appraisal of the evidence from CATT and IVAN. Eye (Lond) 27:289\u2013290","journal-title":"Eye (Lond)"},{"issue":"11","key":"2253_CR69","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.ophtha.2014.05.022","volume":"121","author":"T Ueta","year":"2014","unstructured":"Ueta T, Noda Y, Toyama T et al (2014) Systemic safety of bevacizumab versus ranibizumab for neovascular age related macular degeneration: systematic review and meta-analysis of randomized trials. Ophthalmology 121(11):2193\u20132203","journal-title":"Ophthalmology"},{"key":"2253_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011230.pub2","author":"L Moja","year":"2014","unstructured":"Moja L, Lucenteforte E, Kwang KH et al (2014) Systematic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. Cochrane Database Sist Rev. https:\/\/doi.org\/10.1002\/14651858.CD011230.pub2","journal-title":"Cochrane Database Sist Rev"},{"issue":"7","key":"2253_CR71","doi-asserted-by":"publisher","first-page":"e41325","DOI":"10.1371\/journal.pone.0041325","volume":"7","author":"JW Cheng","year":"2012","unstructured":"Cheng JW, Cheng SW, Lu GC et al (2012) Effect of intravitreal anti-vascular endothelial growth factor therapy on the risk of arterial thromboembolic events: a meta-analysis. PLoS ONE 7(7):e41325","journal-title":"PLoS ONE"},{"issue":"11","key":"2253_CR72","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamaophthalmol.2014.2333","volume":"132","author":"M Thulliez","year":"2014","unstructured":"Thulliez M, Angoulevant D, De Lez ML et al (2014) Cardiovascular events and bleeding risk associated with intravitreal anti-vascular endothelial growth factor monoclonal antibodies: systematic review and meta-analysis. JAMA Ophthalmol 132(11):1317\u20131326","journal-title":"JAMA Ophthalmol"},{"key":"2253_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007325.pub3","author":"T Braithwaite","year":"2014","unstructured":"Braithwaite T, Nanji AA, Lindsley K et al (2014) Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion. Cochrane Data Base Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007325.pub3","journal-title":"Cochrane Data Base Syst Rev"},{"issue":"1","key":"2253_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","volume":"134","author":"RL Avery","year":"2016","unstructured":"Avery RL, Gordon GM (2016) Systemic safety of prolonged monthly antivascular endothelial growth factor therapy for diabetic macular edema: a systematic review and meta-analysis. JAMA Ophthalmol 134(1):21\u201329","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"2253_CR75","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jamaophthalmol.2017.0455","volume":"135","author":"MA Zarbin","year":"2017","unstructured":"Zarbin MA, Dunger-Baldauf C, Haskova Z et al (2017) Vascular safety of ranibizumab in patients with diabetic macular edema: a pooled analysis of patient-level data from randomized trials. JAMA Ophthalmol 135(5):424\u2013431","journal-title":"JAMA Ophthalmol"},{"key":"2253_CR76","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.0002","author":"M Thulliez","year":"2018","unstructured":"Thulliez M, Angoulevant D, Pisella PJ et al (2018) Overview of systematic reviews and meta-analysis on systemic adverse events associated with intravitreal anti vascular endothelial growth factor medication use. JAMA Ophthalmol. https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.0002","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"2253_CR77","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.3928\/23258160-20190503-14","volume":"50","author":"MR Starr","year":"2019","unstructured":"Starr MR, Dalvin LA, AbouChehade JE et al (2019) Classification of strokes in patients receiving intravitreal anti-vascular endothelial growth factor. Ophthalmic Surg Lasers Imaging Retina 50(5):2140\u2013e157","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"5","key":"2253_CR78","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1001\/jamaophthalmol.2018.6891","volume":"137","author":"LA Dalvin","year":"2019","unstructured":"Dalvin LA, Starr MR, AbouChehade JE et al (2019) Association of intravitreal anti-vascular endothelial growth factor therapy with risk of stroke, miocardial infarction and death in patients with exudative age-related macular degeneration. JAMA Ophthalmol 137(5):483\u2013490","journal-title":"JAMA Ophthalmol"},{"key":"2253_CR79","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub6","author":"G Virgili","year":"2018","unstructured":"Virgili G, Parravano M, Evans JR et al (2018) Anti-vascular endothelial growth factor for diabetic macular edema: a network meta-analysis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD007419.pub6","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2253_CR80","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ophtha.2018.09.040","volume":"126","author":"MH Maloney","year":"2018","unstructured":"Maloney MH, Schilz SR, Herrin J et al (2018) Risk of systemic adverse events associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice. Ophthalmology 126(7):1007\u20131015","journal-title":"Ophthalmology"},{"issue":"9","key":"2253_CR81","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1080\/14740338.2019.1643838","volume":"18","author":"C Costagliola","year":"2019","unstructured":"Costagliola C, Morescalchi F, Duse S et al (2019) Systemic thromboembolic adverse events in patients treated with intrvitreal anti-VEGF drugs for neovascular age-related macular degeneration: an update. Expert Opin Drug Saf 18(9):803\u201315","journal-title":"Expert Opin Drug Saf"},{"key":"2253_CR82","unstructured":"AMD-SID (2018) Standard Italiani per la Cura del Diabete Mellito. https:\/\/www.siditalia.it\/pdf\/Standard%20di%20Cura%20AMD%20-%20SID%202018_protetto2.pdf"},{"key":"2253_CR83","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1464-5491.1991.tb01571.x","volume":"8","author":"M Porta","year":"1991","unstructured":"Porta M, Kohner EM (1991) Screening for diabetic retinopathy in Europe. Diabet Med 8:197\u2013198","journal-title":"Diabet Med"},{"key":"2253_CR84","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00592-019-01377-8","volume":"56","author":"G Querques","year":"2019","unstructured":"Querques G (2019) Eye complications of diabetes. Acta Diabetol 56:971","journal-title":"Acta Diabetol"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-019-02253-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11739-019-02253-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-019-02253-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,28]],"date-time":"2024-07-28T19:20:43Z","timestamp":1722194443000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11739-019-02253-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["2253"],"URL":"https:\/\/doi.org\/10.1007\/s11739-019-02253-7","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"9 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"MP has received speaker honoraria from Allergan, Novartis and SIFI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This review article does not describe experimental data derived from procedures carried out in animals or humans by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}